Sample Coordinator

Job description:
 

We want you to feel inspired every day. We’re future-focused and our business is growing. We succeed together through passion, commitment, and teamwork, and so can you.

We are currently recruiting for a Sample Coordinator to join the Process Development team.  The purpose of this role is to provide essential laboratory activities and services supporting the high-quality scientific work conducted at OXB.

Process Development (PD) is responsible for the development of world-class viral vector manufacturing processes for Oxford Biomedica’s proprietary products and partnered programmes. PD performs a crucial technical role in Oxford Biomedica’s mission to deliver life-changing gene therapies to patients.

Your responsibilities in this role would be:

• Receiving and issuing samples for process development purposes as per work schedule.
• Preparing outgoing shipments of samples to other OXB sites, external testing organisations and clients.
• Creating and maintaining inventories of all samples stored within the department.
• Co-ordinating sample requests for analytical assays in a timely manner.
• Supporting Scientists with generation of labels and sample labelling.
• Ensuring a good standard of record keeping.

Profile description:

We are looking for:

• Educated to a minimum of GCSE or equivalent qualification level or able to demonstrate required skills gained within another workplace.
• Highly organised and motivated with excellent attention to details.
• Problem solving skills to help identify way forward when issues arise.
• Computer Literacy skills (MS Office, Word, Excel, Outlook)
• Good communication and interpersonal skills.
• A genuine interest in working in science and/or a Laboratory environment.
• Prev experience in a Laboratory handling biological or chemical examples is preferred but not essential.

About Us:

Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise.

What’s in it for you:

• Highly competitive total reward packages
• Wellbeing programmes
• Development opportunities
• Welcoming, friendly, supportive colleagues
• A diverse and inclusive working environment
• Our values are: Deliver Innovation, Be Inspiring and Have Integrity
• State of the art laboratory and manufacturing facilities

We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you.

Collaborate. Contribute. Change lives.

We offer:

Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.  

Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).  

Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.